70多万种药品“底价”曝光 药企人士称“唯低价论”无益于改革

About 700000 kinds of drugs "price" exposure pharmaceutical company sources said "only the price theory" not conducive to reform

【直报网3月27日讯】（每日经济新闻）恰逢新医改进入第六个年头之际，今年全国两会上，广西花红药业董事长韦飞燕语出惊人，声称九成药品都有降价空间，价格砍掉一半毫无问题。一时间，药价虚高的话题再度被推到医药改革的聚光灯下。

CNDSN March 27th news](Daily News) coincides with the new medical reform enters its sixth year, this year's two sessions, Guangxi Huahong pharmaceutical chairman Wei Feiyan surprising remarks, claiming nine into drugs have price space, price cut half no problem. For a time, the falsely high price of medicine topic again was pushed to the spotlight under medical reform.

在我国药品市场上，由于没有公开的确凿数据，哪怕一些行业内的专家也难厘清药价究竟有多少水分，这更成为百姓、行业外人士不甚了了的灰色地带。

In China's pharmaceutical market, because there is no open hard data, even some experts within the industry is difficult to clarify the price how much water, which become more grey areas, people outside the industry people do.

近日，一位“草根”药改行家的举动撕开了药价的“神秘面纱”，70多万种药品零售价、出厂价的比对清单被其在网站上公布，部分药品的价差高得令人咋舌。

Recently, a "grassroots" drug change experts move slit prices "mystery", about 700000 kinds of drug retail price, ex factory price comparison list is the posted on the web site, part of the medicine spreads is staggering.

中欧国家工商学院卫生管理与政策中心主任蔡江南在接受《每日经济新闻》记者采访时表示，虽然目前没有看到任何官方公布的数据，但据估测，药品零售价比出厂价高出5到6倍是普遍现象。

Center for health management and policy of EU China national industry and commerce institute director Cai Jiangnan in accepting the "daily economic news" reporter the interview said, although do not see any official data, but it is estimated, drug retail price higher than the ex factory price of 5 to 6 times is a common phenomenon.

药品底价遭某网站曝光

The drug price was a website exposure

《长江商报》近日的一则报道，将卫柏兴和他的“降药价网”再次推到公众面前。卫柏兴自称“草根”药改行家，从1997年开始从事医药销售职业，并在2011年创立了降药价网。该网站显示，这是一家已经取得互联网药品信息服务非经营性资格证的网站。在该网站上，共列出含70多万种药品零售价、出厂价的比对清单，同时也列出了药品名称、规格、剂型以及生产厂家。

"Changjiang Daily" recently in a report, the Wei Bai Xing and his "drop prices net" once again to the public. Wei Baixing claiming to be "grassroots" medicine instead of experts, from the beginning of 1997 engaged in pharmaceutical sales career, and founded the drop prices net in 2011. The site shows, this is a have made drug information service on the Internet website of the non operating qualification certificate. In this website, listed comparison list containing about 700000 kinds of drug retail price, ex factory price, also lists the drug name, dosage form, specification and manufacturers.

记者浏览降药价网发现，有不少药品的零售价是出厂价的七八倍。例如，一款头孢尼西注射剂，每支0.5g的规格零售价为32.8元，而出厂价仅为4.9元；同样，片剂贝沙坦氢氯噻嗪片是治疗原发性高血压的常用药，162.5mg×7的规格零售价38.07元，出厂价为4.75元。

Reporter browse drop prices finds, there are a lot of drug retail price is seven or eight times of the ex factory price. For example, a cefonicid injection, each 0.5g specifications retail price is 32.8 yuan, while the ex factory price of only 4.9 yuan; similarly, irbesartan and hydrochlorothiazide tablets is commonly used drugs in the treatment of primary hypertension, 162.5mg x 7 specifications of the retail price of 38.07 yuan, the ex factory price of 4.75 yuan.

这些药品底价究竟从何得知？卫柏兴在接受《每日经济新闻》记者采访时表示，降药价网在全国各个省市共设有40个数据采集点，包括医药公司、连锁药店、个人代理和药厂的业务员。有一部分数据是降药价网花钱买来的。“我们已大约花了几十万来购买药企的数据，手里有非常多的药价单。按条收费，根据传真数量不同，我们可能每月要花费八千元。”卫柏兴表示，来自药企的价格数据大约占全部的60%。

The drugs price after all from why that? Wei Baixing told the "daily economic news" interview with reporters, drop prices net in various provinces and municipalities with a total of 40 data points, including the Medicines Co, chain stores, individual agent and pharmaceutical salesman. There is a part of the data is to drop prices net bought. "We have spent about hundreds of thousands of dollars to buy Pharmaceutical data, hand very much a single drug prices. According to the charges, according to the fax number is different, we may have a month to spend eight thousand yuan." Wei Baixing said, the price data from pharmaceutical companies for about 60% of the total.

针对药品底价可靠性的质疑，卫柏兴解释说，降药价网会比较同类药品不同药企提供的价格，通常情况下，差异不会超过10%到20%，“其实药价在行业里一直是透明的，只不过我们把这个行业都明白的事公布给公众而已，价格(数据)真实可靠没有任何问题。”

Drug price question the reliability of Baixing, Wei explained, the network will drop prices compared with a similar drug pharmaceutical companies provide different prices, usually, the difference will not be more than 10% to 20%, "in fact, prices in the industry has always been transparent, but we put this industry understand things to the public, the price (data) is true and reliable without any problems."

药企人士称无益于价格改革

Pharmaceutical companies sources not conducive to price reform

针对降药价网揭露药企产品出厂底价的做法，和黄制药一位负责人对《每日经济新闻》记者表示，药品的招商价格应是行业内公开的，虽然目前药企同类药品出厂价格会有差异，但药企都会按照规定将药品的成本价格和批发价格上报国家有关部门，并经过审批。

To drop prices net pharmaceutical product factory price disclosure practices, and yellow pharmaceutical official said on the "daily economic news" reporter, drug investment prices should be within the industry open to the public, although the pharmaceutical companies of similar drugs ex factory prices vary, but pharmaceutical companies will be in accordance with the provisions of the drug cost price and the wholesale price reported to the relevant departments of the state, and after approval.

东盛集团董事张斌在接受《每日经济新闻》记者采访时表示，如果公布所谓的药品“底价”是唯低价是取，那么这种做法只考虑到药品的原材料成本，置研发及创新成本于不顾，这种做法无益于药品价格的改革，还有可能引发经典配药的短缺。“纯粹追求低价，就连药企的合理利润也被挤压在外，导致药企被迫停产一些常用药，这也正是国家出台相应低价药品保护政策的原因。”张斌对记者说，“比如抗生素，因为药价过低，药企放弃生产第一代头孢类产品，转而生产药效更强的二代甚至三代头孢类药，不仅价格不断上涨，也没有考虑到患者耐药性带来的后果。”

Dongsheng Group Director Zhang Bin in accepting the "daily economic news" reporter the interview said that if published the so-called drug "price" is only the price is taken, so that only considering the drug raw material costs, the cost of R & D and innovation in disregard of, this is not conducive to the reform of drug prices, shortage is also a cause of classic dispensing. "Pure pursuit of cheap, even a reasonable profit pharmaceutical companies has also been squeezed in the outside, resulting in pharmaceutical enterprises were forced to stop production of some commonly used drugs, this is why the state promulgated corresponding low-priced drugs protection policy." Zhang Bin told reporters, "such as antibiotics, because the price is too low, pharmaceutical companies to abandon the production of first generation cephalosporins product, turned to the production of stronger two and even three generation cephalosporins, not only prices continue to rise, also does not take into account the consequences of drug resistance in patients with."

当被问到降药价网上公布的药品虚高情况是否符合实际时，张斌表示并不知情，且中西药等不同药品种类和地区的定价做法不尽相同。

When asked to drop prices published online virtual high drug whether accord with actual, Zhang Bin said did not know, and different types of drugs of traditional Chinese medicine and Western medicine and regional pricing practices are not the same.

北京鼎臣医药咨询负责人史立臣向《每日经济新闻》记者介绍了目前我国药品流通定价的流程。药品在招标环节分为基础药品和非基础药品，前者基本上包含在医保药品目录中，后者有一部分已经列入医保，剩下的还在医保之外。各省在药品集中采购平台认购中标药品后，公立医院为了进一步压低药价，还会进行二次议价。

Beijing Dingchen medical consultation person in charge Shi Lichen introduced the present drugs pricing in China in the process to the "daily economic news" reporter. Drugs in the bidding link is divided into basic drugs and non basic drugs, the former basically included in the medical insurance drugs directory, the latter part is already included in the medical insurance, the rest is still outside the medical insurance. The provinces in the centralized drug procurement platform subscription bid drugs, public hospitals in order to further push down prices, also carries on two times of bargaining.

The main problem lies in the link of tendering

目前，药价高、看病难依然没有得到更多改善。

At present, high drug prices, see a doctor difficult still did not get more improvement.

史立臣认为，药价虚高问题主要出在招标环节。一些药企在上报药品零售价时，不仅已将专利、独家研发等成本囊括进去，甚至还包括了二次议价、医院医生收取回扣的成本。究竟药企应有多少合理利润率？史立臣估测，流通类药企的利润率在4%到7%；OTC类在10%左右；而销售到医院的常用和独家药品可为企业带来17%到20%的利润。

Shi Lichen thinks, the falsely high price of medicine the main problem lies in the link of tendering. Some enterprises in the reporting of drug retail price, not only has the exclusive patent, such as research and development costs included, even included two bargaining, the hospital doctors receive kickbacks cost. How much they should reasonable profit margin? Shi Lichen estimation, circulation industry profit margins in the 4% to 7%; the OTC class in about 10%; and sales to the hospital of the commonly used and exclusive drugs can bring 17% to 20% for the profits of enterprises.

卫柏兴认为，药价水分虚高的背后是利益集团的垄断。他对《每日经济新闻》记者透露，我国总共四五千家药企中，只有二三百家做得不错，其余大多数都是微利或亏损状态。有些药品销售排名靠前的企业，在公立三级甲等医院的销售占据垄断地位。同样，医院药品销售占全部药品销售总比的80%以上。

Wei Baixing think, behind the falsely high price of medicine water is interest group monopoly. He told the "daily economic news" reporter, a total of four thousand or five thousand companies in China, only two hundred or three hundred have done well, and most of the rest are small profit or loss of status. Some drug sales ranking enterprise, has a monopoly on public three level of first-class hospital sales. Similarly, the hospital drug sales accounted for the total ratio of more than 80% of drug sales.

2014年11月25日，国家发改委下发的《推进药品价格改革方案(征求意见稿)》显示，政府定价角色在未来药品的形成机制中基本淡出，取消最高零售限价，医保药品的价格由医保部门接手制定支付基准价，医院采购时围绕医保支付基准价协商谈判，加强医院的议价动力；专利药和中成药独家品种等药品则引入多方谈判机制。

In November 25, 2014, the national development and Reform Commission issued the "promotion of drug price reform program (Draft)" shows the basic role of government pricing, fade out in the future in the formation mechanism of drug, cancel the maximum retail price, the price of medical insurance drugs by medical insurance departments to pay over the benchmark price, hospital procurement around the Medicare payment benchmark price negotiation, bargaining power to strengthen hospital; patent medicine and Chinese medicine exclusive varieties drugs introduced multi-party negotiation mechanism.

中国医院协会秘书长庄一强对《每日经济新闻》记者介绍说，目前我国已经逐步开始实施取消药品最高零售限价的政策，开始向卫生系统负责的中标价和人社部牵头的医保价转变。

China Hospital Association Secretary General Zhuang Yiqiang to the "daily economic news" reporter said, at present our country has gradually begun to implement cancel drug maximum retail price policy, began to health system responsible for the price and the Department led the insurance price change.

蔡江南对记者表示，目前药企单方面向发改委提供药价存在弊端，不具备科学依据，因此未来我国的药品价格改革应继续推进包括医疗单位、药厂在内的协商机制。

Cai Jiangnan expresses to the reporter, at present the pharmaceutical companies to the development and Reform Commission provide single price malpractice, does not have the scientific basis, so the future of drug price reform in China should continue to push forward the negotiation mechanism including medical units, pharmaceutical.

史立臣坦言，目前全国存在多种药品价格改革的试行方案，其中湖南的药品指导价格被专家砍掉一半，而浙江更是直接参考全国最低价位。目前还没有发现一种最有效的方案，政府和市场也在摸着石头过河。▲

Shi Lichen said, at present the national existence the pilot scheme a variety of drug price reform, including Hunan's drug price guide experts were cut in half, and Zhejiang is the lowest price directly reference. Has not found a most effective solution, the government and the market in crossing the river by feeling the stones. *

（原标题：70多万种药品“底价”曝光 售价普遍超出厂价5到6倍)

(original title: about 700000 kinds of drug exposure "price" prices generally exceed priced at 5 to 6 times)

责任编辑：婉婉

Editor: Che Wan Wan